Seattle Genetics SGEN releases its next round of earnings Thursday. Here's Benzinga's essential guide to Seattle Genetics's [quarter] earnings report.
Earnings and Revenue
Wall Street expects an EPS loss of 39 cents and sales around $141.04 million.
In the same quarter last year, Seattle Genetics reported a loss per share of 39 cents on sales of $108.22 million. Revenue would be up 30.32 percent from the year-ago period. Seattle Genetics's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | -0.41 | -0.45 | -0.42 | -0.42 |
| EPS Actual | -0.61 | -0.41 | 0.34 | -0.39 |
Stock Performance
Over the last 52-week period, shares are up 28.93 percent. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. Analyst estimates have not been modified for EPS and revenues over the past 90 days. The most common rating by analysts on Seattle Genetics stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
Seattle Genetics' Q2 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here: https://edge.media-server.com/m6/p/bocxtr5h
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
